Considerations for Sponsors Conducting Protocol Feasibility and Review

For emerging biopharma companies preparing to launch a clinical trial, protocol development is one of the most critical and risk-prone steps. A robust, cross-functionally informed protocol feasibility and review process is one of a sponsor’s strongest tools to prevent mid-study protocol amendments.

Protocol design flaws are a common, yet preventable, threat to the success of a clinical trial. Typically not discovered until a trial is already underway, these issues might appear in the form of recruitment failures, excessive protocol deviations, and poor data integrity.

Ultimately, once identified, many flaws can be resolved through the implementation of a protocol amendment. Unfortunately, even just a single amendment can be a six-figure cost that pushes trial timelines back months.

Bring together a senior multi-disciplinary group to assess your protocol

Updated ICH E6(R3) guidance stresses the importance of incorporating stakeholder input early in the process. In addition to ensuring your trial follows both a patient-centric and risk-based approach, a multi-disciplinary group can help sponsors put fresh eyes and operational perspectives on their protocol to pinpoint potential areas of concern or ambiguity.

 

Who should this group include?

Outside of perspectives from the sponsor and relevant patient populations, the operational review of a protocol should involve:

  • Biostatisticians
  • Medical monitor/advisors (MD)
  • Pharmacologists
  • Clinical trial operations specialists
  • Data managers
  • Investigators

 

What should your multi-disciplinary group provide input on?

This group should plan to provide input on aspects such as:

  • Statistical design and powering checks
  • Dosing and PK/PD feasibility review
  • Visit flow and scheduling window analysis
  • Safety signal and AE risk projections
  • Investigator and site compliance assessment
  • Retention and dropout risk modeling
  • Input on protocol clarity and refinement

How PharPoint helps sponsors strengthen protocol feasibility

PharPoint’s protocol review and stress-testing services are designed to support supports with a thorough, multi-disciplinary review and suggestions for a clear path forward.

Our clinical trial protocol review services include:

A written Protocol Risk Report summarizing key findings and mitigation recommendations

An optional Excel-based simulation model (e.g., retention or dosing scenarios)

A 60 minute virtual workshop with your team to review results and agree on fixes

Our aim in offering this service is to prevent costly mid-study amendments; reduce screen failures, dropouts, and protocol deviations; protect study timelines and budgets; and build confidence with internal and external stakeholders.


Final Thoughts

Protocol feasibility and review is a strategic opportunity to de-risk your study and set your team up for success. By engaging the right experts and using data-driven tools to assess operational realities, sponsors can avoid potential pitfalls and move forward with confidence.

If you are looking for protocol optimization support, PharPoint’s team is here to help. Reach out to our team for more information.


RELATED RESOURCES

Fit Matters – CROs are Not All the Same | PharPOV Series

Fit Matters – CROs are Not All the Same | PharPOV Series

When it comes to CRO selection, fit matters, and not every vendor is the same. Hear from PharPoint co-founder Audra ...
In Clinical Research, AI Cannot Be A Substitute for Judgement | PharPOV Series

In Clinical Research, AI Cannot Be A Substitute for Judgement | PharPOV Series

Exec. Director of Strategy Development Paul Johnson talks about the use of AI in clinical research in this month's PharPOV ...
Assessing Quality Culture | PharPOV Series

Assessing Quality Culture | PharPOV Series

How mature is your organization’s quality culture? Hear from PharPoint's Director of Quality Assurance ...
Navigating Complexity in Pulmonary Trials | PharPOV Series

Navigating Complexity in Pulmonary Trials | PharPOV Series

Exec. Dir. Strategy Development Paul Johnson kicks off the first article in a series on pulmonary trial design ...
AI in Clinical Research | PharPOV Series

AI in Clinical Research | PharPOV Series

How can we make sure artificial intelligence (AI) is used ethically and responsibly in clinical research? Hear from PharPoint's VP ...
When Customer Service Isn't Enough | PharPOV Series

When Customer Service Isn’t Enough | PharPOV Series

PharPoint's Exec. Director of Client Experience explains where customer service can fall short, based on conversations after a recent move ...
Written by: Theresa Hegar